Discovery of a potent dual ALK and EGFR T790M inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) mutations drive non-small cell lung cancer (NSCLC) progression.
• Acquired resistance to targeted therapies, particularly EGFR inhibitors, is a significant clinical challenge.
• Reciprocal activation between ALK and EGFR pathways can lead to treatment failure.

Purpose of the Study:

• To develop novel small molecule inhibitors with dual activity against ALK and EGFR.
• To specifically target the T790M EGFR mutation, a common cause of resistance.
• To investigate the potential of dual inhibitors in overcoming resistance mechanisms in NSCLC.

Main Methods:

• Design and synthesis of novel small molecule compounds.
• Enzymatic and cellular assays to evaluate inhibitory activities against ALK and EGFR mutants.
• Testing lead compounds in patient-derived NSCLC cell lines harboring relevant mutations.
• Assessment of signaling pathway modulation and antiproliferative effects.

Main Results:

• Identification of a lead compound (7c) with potent dual inhibitory activity against ALK and EGFR (including T790M).
• Compound 7c demonstrated significant inhibition in enzymatic and cellular assays.
• 7c effectively recapitulated the effects of combined approved ALK and EGFR inhibitors in a resistant NSCLC cell line.
• Demonstrated antiproliferative activity in a patient-derived NSCLC cell line with both EML4-ALK and activated EGFR.

Conclusions:

• Dual ALK/EGFR inhibitors represent a promising therapeutic strategy for NSCLC.
• The lead compound 7c shows potential for overcoming resistance mediated by ALK and EGFR co-activation.
• Targeting both ALK and EGFR simultaneously may prevent the emergence of resistance in NSCLC treatment.